Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.66 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.64 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.64 |
| ▸ | LTA4H | P09960 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | ESRRB | O95718 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10148136 | 0.91 | HRH3 (0.67) | HRH3KEAP1NFE2L2LTA4HKDM4E | |
| SCHEMBL25443770 | 0.85 | TDP1 (0.48) | LTA4H | |
| SCHEMBL8252571 | 0.83 | CYP1A2 (0.62) | HRH3LTA4HKDM4E | |
| SCHEMBL10897314 | 0.83 | HRH3 (0.72) | HRH3KEAP1NFE2L2LTA4HKDM4E | |
| SCHEMBL15307617 | 0.83 | SLC2A1 (0.49) | HRH3 | |
| SCHEMBL8251192 | 0.81 | LTA4H (0.51) | HRH3KEAP1NFE2L2LTA4HKCNH2 | |
| SCHEMBL14160620 | 0.81 | PPARG (0.58) | HRH3KEAP1NFE2L2LTA4HKDM4E | |
| SCHEMBL15267191 | 0.80 | CHRNB2 (0.58) | HRH3KEAP1NFE2L2LTA4HKDM4E | |
| SCHEMBL14668123 | 0.80 | HRH3 (0.68) | HRH3KEAP1NFE2L2LTA4HKDM4E | |
| SCHEMBL8245062 | 0.80 | TSHR (0.69) | LTA4HKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022119756-A9 | COMPOSITIONS AND METHODS FOR INHIBITING M PRO PROTEASE ACTIVITY AND FOR PREVENTING AND TREATING SARS-COV-2 INFECTION | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-04-27 | — | — | WO | disclosed |
| US-8541455-B2 | Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof as HIF activators | SANOFI (FR) | 2013-09-24 | — | — | US | disclosed |
| US-20110294788-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS | SANOFI (FR) | 2011-12-01 | — | — | US | disclosed |
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | disclosed |
| US-7300936-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | APP, APBA1, BACE1 | HRH3 1065/4885KEAP1 2951/4885NFE2L2 1532/4885 |
| US-20110294788-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS | HIF1AN, HIF1A, EGLN2 | HRH3 1331/4885KEAP1 146/4885NFE2L2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.